Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
This article was originally published in The Pink Sheet Daily
Executive Summary
The financing is a first where a Korean start-up was able to attract an international syndicate of this stature, OrbiMed Caduceus Asia Partners Managing Director Chang said
You may also be interested in...
Novartis To Sell Flu Vaccine Adjuvant To Korea's Green Cross
SEOUL - South Korean vaccine maker Green Cross recently signed a deal with Novartis to buy the latter's adjuvanted A/H1N1 vaccine MF59 to expand Green Cross' A/H1N1 vaccine production volume
Biotech, Small Pharma IPO Market Frozen For At Least Next Year, VCs Say – Bio Korea
OSONG, South Korea - The worldwide market for biotech and other pharmaceutical companies seeking funds through initial public offers is closed for at least a year and other sources of money are becoming scarce as well, venture capital firms said during the annual Bio Korea conference in Osong, South Korea
Life Sciences Investors Talk Shop On Asia Opportunities – Singapore Conference
SINGAPORE - The swing from big pharma to biotech has captured investor attention, and has changed the nature of the types of investments that venture capitalists are making. Many are willing to take bigger risks in Asia and are opting in earlier rather than as pipelines mature, making intellectual property protection even more critical, a panel of investors said during the BioMedical Asia 2008 conference in Singapore April 15